– Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab –
SAN DIEGO and SUZHOU, China, Dec 7 (Bernama-GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced clinical data on its anti-CTLA-4 monoclonal antibody, ADG116, and anti-CD137 agonist, ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021, to be held virtually and in Geneva, Switzerland from December 8 to 11, 2021. Both posters are available in the Publications section of the company’s website at www.adagene.com.
- US completes deportation of 8 men to South Sudan after weeks of legal wrangling
- Iran’s Supreme Leader Attended Mourning Ceremony In Tehran
- Zionist Israeli Army Claims Control Of 65 Percent Of Gaza; Death Toll: 57,130+ Palestinians
- Brazil: Rio de Janeiro gears up for BRICS Summit
- DR Congo gov’t, M23 rebels to hold new round of talks in Doha: AFC official
- 45 Opposition Party Members In Türkiye’s Izmir Arrested On Corruption Charges
- Iran Reaffirms Commitment To Diplomacy, Urges Reciprocal Action
- DPRK Condemned Denuclearisation Calls By U.S.-Led Quad
- S. Korea’s Parliament Approves Prime Minister Nominee
- Russia Becomes First Country To Formally Recognise Taliban Government